Back to News
Market Impact: 0.5
Novartis signs mRNA deal for about $7.8 billion with China's Abogen
Source: reuters.com
Healthcare & BiotechM&A & RestructuringTechnology & Innovation
Chinese biotech Abogen signed a licensing agreement with Novartis valued at approximately $7.8 billion to advance RNA-based therapies. The deal provides major validation and potential funding for Abogen's RNA platform while expanding Novartis's access to the technology.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
NVS0.75
More News
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Abogen signs $7.2 bln Novartis deal for mRNA autoimmune drug
- Mark Ruffalo says Paramount’s $111 billion Warner Bros. deal ‘Will stifle creativity, weaken free speech, and cost people their jobs’
- David Ellison says combined Paramount and Warner Bros. Discovery will be named Skydance
- Paramount and Warner Bros Discovery to become Skydance
- Paramount’s Warner Bros. megamerger will just be called Skydance